Contact us

532 Results:

Sort By:

Use of an exclusive human milk diet in preterm infants to lower healthcare costs – short-term and long-term perspectives

Type: Prolacta in the News

Topic(s): Cost Savings / Cost Effectiveness Long-Term outcomes Pasteurization

Prolacta Bioscience provides update on latest SARS-CoV-2 data and continued safety of its human milk-based nutritional products

Type: Press Releases

Topic(s): Quality & Safety

Prolacta’s manufacturing team shines in 2020

Type: Employee Stories

Topic(s): Quality & Safety

Donor Stephanie

Type: Donor Stories

Topic(s): Tiny Treasures

Donor Abbie gives back

Type: Donor Stories

Topic(s): Tiny Treasures

Donor Jade

Type: Donor Stories

Topic(s): Tiny Treasures

Late-onset sepsis reduced in premature infants fed Prolacta’s 100% human milk-based fortifiers as part of an exclusive human milk diet

Type: Press Releases

Topic(s): Clinical Studies Clinical Studies on Prolact/Humavant CR Late-Onset Sepsis

Prolacta Bioscience fortifiers reduce risk of serious lung disease and hospital costs among premature infants, compared to cow milk-based fortifiers

Type: Press Releases

Topic(s): Bronchopulmonary Dysplasia (BPD)

Donor Lindsey

Type:

Topic(s):

Not finding the reference you’re looking for?

Email us at info@prolacta.com